Health Technology Assessment (HTA) of GLP-1 receptor agonists and SGLT-2 inhibitors in combination with metformin as first-line treatment in patient with type 2 diabetes mellitus (T2DM) and established cardiovascular or chronic kidney disease

Eline Aas, Monica Gomez and Fawaz Tariq
Additional contact information
Monica Gomez: Department of Health Management and Health Economics, Postal: HERO / Department of Health Management and Health Economics, P.O. Box 1089 Blindern, NO-0317 Oslo, Norway
Fawaz Tariq: Department of Health Management and Health Economics, Postal: HERO / Department of Health Management and Health Economics, P.O. Box 1089 Blindern, NO-0317 Oslo, Norway

No 2022:3, HERO Online Working Paper Series from University of Oslo, Health Economics Research Programme

Abstract: Type 2 diabetes mellitus (T2DM) is one of the most prevalent lifestyle-related diseases, causing increased mortality, morbidity and reduction in health-related quality of life (HRQoL), as well as costs to society related to treatment, follow-up and production losses.In the current guidelines, SGLT-2 inhibitors and GLP-1 analogs are recommended as second-line treatment for T2DM. Based on results from recent studies, we have in this report analyzed whether these drugs can be considered cost-effective as first-line treatment (in combination with metformin) for patients with T2DM with either established cardiovascular disease or chronic renal failure (only SGLT-2 inhibitors considered). Based on two decision analytic models we estimated the incremental cost per QALYs gained. For the patients with T2DM and established CVD, SGLT-2 i is the preferred alternative (ICER NOK 59,811 per LY gained and NOK 89,517 per QALY gained) and is superior to GLP-1 RA, as SGLT-2 I resulted in higher health outcomes than GLP-1 RA. For patients with T2DM and established renal failure when comparing SGLT-2 i to metformin results in an ICER of NOK 168,872 per LY gained and NOK 193,656 per QALY gained. Both ICERs fall below the the threshold for these two patient groups are NOK 475,000

Keywords: Type 2 diabetes; retningslinjer; kostnadseffektivitetsanalyse; SGLT-2 I; GLP1-RA (search for similar items in EconPapers)
JEL-codes: C52 D61 H51 (search for similar items in EconPapers)
Pages: 67 pages
Date: 2022-10-19
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.med.uio.no/helsam/forskning/nettverk/h ... erie/2022/2022-3.pdf Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:oslohe:2022_003

Access Statistics for this paper

More papers in HERO Online Working Paper Series from University of Oslo, Health Economics Research Programme HERO / Department of Health Management and Health Economics P.O. Box 1089 Blindern, N-0317 Oslo, Norway. Contact information at EDIRC.
Bibliographic data for series maintained by Kristi Brinkmann Lenander ().